This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
by Zacks Equity Research
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
Company News for Sep 21, 2021
by Zacks Equity Research
Companies In The News Are: TSLA, AAL, PFE, BNTX, F.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.20, marking a +0.71% move from the previous day.
September Syndrome Deepens in Markets
by Zacks Equity Research
September Syndrome Deepens in Markets.
Contagion Fears Squeeze Pre-Market Futures
by Mark Vickery
It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
by Zacks Equity Research
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
by Zacks Equity Research
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Markets Melt Down on Profit Taking, Not Economic Logic: 5 Picks
by Nalak Das
We have narrow down the search to five stocks that have provided double-digit returns year to date. These are: HPQ, LKQ, KSS, M and X.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.71, marking a +0.29% move from the previous day.
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
by Zacks Equity Research
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
5 Top-Ranked Large-Cap Stocks That Have Skyrocketed YTD
by Nalak Das
We have narrowed down our search to five large-cap stocks with strong potential for the rest of 2021. These are: NUE, ON, KMX, ORLY and ULTA.
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
Will COVID-19 Vaccines for Children be Available by Year-End?
by Zacks Equity Research
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.
Why U.S. Airline Stocks Gained Yesterday Despite Dim Views
by Maharathi Basu
Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.
Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?
by Zacks Equity Research
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
ETFs in Focus on Airlines' Slowdown Warnings
by Sweta Killa
The slew of revenue warnings comes with signs of recovery, thereby leading to spike in airline stocks.
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
by Zacks Equity Research
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
by Kinjel Shah
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC